MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion

[1]  H. Schild,et al.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? , 2013, EPMA Journal.

[2]  I. Sayers,et al.  Urokinase Receptor Orchestrates the Plasminogen System in Airway Epithelial Cell Function , 2013, Lung.

[3]  M. Rosemann,et al.  Effects of Simultaneous Knockdown of HER2 and PTK6 on Malignancy and Tumor Progression in Human Breast Cancer Cells , 2013, Molecular Cancer Research.

[4]  H. Braselmann,et al.  Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells , 2012, Radiation oncology.

[5]  Aamir Ahmad,et al.  The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis , 2012, International journal of molecular sciences.

[6]  Jiao-Yang Li,et al.  MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2 , 2012, Medical Oncology.

[7]  L. Wang,et al.  MicroRNA-mediated breast cancer metastasis: from primary site to distant organs , 2012, Oncogene.

[8]  E. Howe,et al.  The miR-200 and miR-221/222 microRNA Families: Opposing Effects on Epithelial Identity , 2012, Journal of Mammary Gland Biology and Neoplasia.

[9]  Satoru Takahashi,et al.  Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer , 2011, Breast Cancer Research and Treatment.

[10]  J. Steitz,et al.  Posttranscriptional activation of gene expression in Xenopus laevis oocytes by microRNA–protein complexes (microRNPs) , 2011, Proceedings of the National Academy of Sciences.

[11]  Maria Kafousi,et al.  MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer , 2011, Cell cycle.

[12]  D. Yee,et al.  MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer , 2010, Hormones & cancer.

[13]  X. Ye,et al.  Rnai-mediated Downregulation of Upar Synergizes with Targeting of Her2 through the Erk Pathway in Breast Cancer Cells , 2022 .

[14]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[15]  P. Pu,et al.  MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN , 2010, BMC Cancer.

[16]  F. Ferrari,et al.  A MicroRNA Targeting Dicer for Metastasis Control , 2010, Cell.

[17]  M. Raffeld,et al.  C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway , 2010, Haematologica.

[18]  Hansjuerg Alder,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[19]  C. Croce,et al.  MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Gian Luca Grazi,et al.  MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality , 2009, Clinical Cancer Research.

[21]  I. Sayers,et al.  Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells , 2009, BMC Molecular Biology.

[22]  C. Kang,et al.  Analysis of miR-221 and p27 expression in human gliomas. , 2009, Molecular medicine reports.

[23]  Å. Borg,et al.  MiRNA expression in urothelial carcinomas: Important roles of miR‐10a, miR‐222, miR‐125b, miR‐7 and miR‐452 for tumor stage and metastasis, and frequent homozygous losses of miR‐31 , 2009, International journal of cancer.

[24]  H. Höfler,et al.  Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer , 2008, Journal of hematopathology.

[25]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[26]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[27]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[28]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[29]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[30]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[31]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[32]  Reuven Agami,et al.  Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation , 2007 .

[33]  S. Shetty,et al.  Regulation of Urokinase Receptor Expression by p53: Novel Role in Stabilization of uPAR mRNA , 2007, Molecular and Cellular Biology.

[34]  A. Walch,et al.  PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas , 2007, British Journal of Cancer.

[35]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[36]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[37]  S. Shetty.  Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells , 2005, Molecular and Cellular Biochemistry.

[38]  Y. Nagamine,et al.  Stabilization of Urokinase and Urokinase Receptor mRNAs by HuR Is Linked to Its Cytoplasmic Accumulation Induced by Activated Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 , 2003, Molecular and Cellular Biology.

[39]  N. Harbeck,et al.  Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[41]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[42]  B. Nielsen,et al.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.

[43]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[44]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[45]  Reuven Agami,et al.  Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. , 2007, The EMBO journal.